# Vitamin D supplementation in pregnancy: A word of caution.

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>Annals of Clinical Biochemistry</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>ACB-19-282.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Case Report</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>05-Dec-2019</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Macdonald, Christy; Canterbury District Health Board, Department of Endocrinology  
                          | Upton, Thomas; Canterbury District Health Board, Department of Endocrinology  
                          | Soule, Steven; Canterbury District Health Board, Endocrinology;  
                          | Canterbury District Health Board, General medicine  
                          | Hunt, Penny; Canterbury District Health Board, Department of Endocrinology  
                          | Florkowski, Christopher; Canterbury Health Laboratories, Biochemistry  
                          | Phillips, Ian; Canterbury Health Laboratories, Department of Biochemistry  
                          | Kaufman, Martin  
                          | Jones, Glenville |
| Keywords:      | Calcium < Analytes, Inborn errors of metabolism < Clinical studies, Mass spectrometry < Laboratory methods |
Vitamin D supplementation in pregnancy: A word of caution.

Familial hypercalcaemia due to disordered vitamin D metabolism

Christy Macdonald¹, Thomas Upton¹, Penny Hunt¹, Ian Phillips², Martin Kaufmann³, Chris Florkowski², Steven Soule¹, Glenville Jones³

¹Department of Endocrinology, Christchurch Hospital, New Zealand; ²Canterbury Health Laboratories, Christchurch, New Zealand, ³Department of Biomedical and Molecular Sciences, Queen’s University, Ontario, Canada

DECLARATIONS

Competing interests: None

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical approval: not applicable

Guarantor: CM

Contributorship: CM and TU reviewed the literature and wrote the manuscript. All authors reviewed and edited the manuscript and approved the final version.

Acknowledgements: We would like to thank the index case for her consent to publish and the Molecular Genetics Laboratory at Labplus, Auckland for performing the genetic analysis in this case. We acknowledge the loan of the LC-tandem mass spectrometer used in these studies as part of a Waters-Queen’s University Research Agreement.

Abstract:

Disorders of vitamin D metabolism have only recently become more widely recognised. In 2011, a series reported six children with familial idiopathic infantile hypercalcaemia, a condition in which patients develop hypercalcemia following bolus vitamin D
supplementation due to mutations in CYP24A1, formerly known as 24-hydroxylase. This is the chief enzyme in catabolism of 1,25-dihydroxyvitamin D$_3$ (calcitriol) to inactive 1,24,25-(OH)$_3$D$_3$ \(^1\). Isolated cases of loss of function CYP24A1 mutations have been reported across a wide spectrum of ages, including three cases first identified during pregnancy in the context of vitamin D supplementation.\(^2,3,4\)

We describe a family in which two siblings had hypercalcaemia due to a disorder of calcitriol catabolism as a result of compound heterozygous loss of function mutations of CYP24A1, including a novel mutation K351Nfs*21. The index case, who has kindly given written informed consent for this report, was a female in her mid-20s presenting with symptomatic hypercalcaemia precipitated by vitamin D supplementation in her first pregnancy. In a subsequent pregnancy, she remained normocalcaemic in the absence of supplementation. Her asymptomatic brother was identified through cascade screening. Upregulation of calcitriol production in pregnancy, particularly when combined with vitamin D supplementation, can unmask previously unidentified disorders of vitamin D metabolism. This report emphasises the importance of screening of family members and the need for caution with vitamin D supplementation in pregnancy.

**Keywords:** CYP24A1, Idiopathic infantile hypercalcemia, Vitamin D supplementation, pregnancy, hypercalcaemia, 24,25-(OH)$_2$D$_3$

**Case description**

A previously healthy primigravida in her mid-20s presented with hyperemesis and hypercalcaemia at 13 weeks' gestation and was referred for endocrinological assessment. Prior to the pregnancy, her general practitioner had diagnosed mild vitamin
D deficiency (25-OH-D₃ 30 nmol/l [reference interval (RI) 50-150] and prescribed monthly supplementation (colecalciferol 50,000 units daily for 12 days then monthly for a total of 3 months). Examination was as expected for gestation and there was no clinical suspicion of malignancy, infection or an inflammatory process.

Laboratory investigations revealed elevated albumin-corrected plasma calcium 2.9 mmol/L [RI 2.2-2.6] (11.6mg/dL), normal phosphate 1.1 mmol/L [RI 0.8-1.5], (3.41mg/dL), low parathyroid hormone 0.7 pmol/L [RI 1.6-7.0] (6.6 pg/mL) and normal renal function. 25-OH-D₃ was normal at 116nmol/l. Urine calcium excretion was markedly elevated at 2.09 mole ratio [RR 0.06-0.45]. Plasma 1, 25-(OH)₂D₃ (calcitriol) was twice the upper limit of the normal reference range at 380 pmol/L [RI 65-175].

Parathyroid hormone related peptide (PTHrP) was undetectable at 20 weeks’ gestation.

Abdominal ultrasound showed a 5mm asymptomatic renal calculus and normal uterine anatomy appropriate for gestation. Chest x-ray was normal, serum angiotensin converting enzyme (ACE) was normal, and a QuantiFERON-TB Gold test was negative.

DEXA bone densitometry performed 2 months prior to pregnancy was normal for age.

Vitamin D supplementation was discontinued. A trial of prednisone (20mg daily for 14 days) had no effect on plasma calcium which remained between 2.9-3.3 mmol/l throughout the remainder of her pregnancy. At 36 weeks’ gestation she developed idiopathic cholestasis of pregnancy (ICP) and delivered a healthy normocalcemic infant at term. Hypercalcemia resolved by 4 weeks’ post-partum, although hypercalciuria persisted.

A diagnosis of disordered calcitriol catabolism was considered and samples were sent to a specialised international laboratory for the analysis of vitamin D metabolites. The
results are shown in the Table 1, and Figure 1. Quantitative assay of vitamin D metabolites was performed by modified liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology using a chromatographic approach that resolves 24,25(OH)2D3 from 25,26(OH)D3. The ratio of plasma 25-OH-D3 to 24, 25-(OH)2D3 was markedly elevated. In addition, 1,24,25(OH)3D3 levels were undetectable confirming lack of functional CYP24A1.

Genetic analysis using PCR and DNA sequencing of the entire genome coding region and splice junctions was performed. Compound heterozygous loss-of-function mutations of CYP24A1 were detected (Figure 1). The E143del mutation has previously been reported in association with the condition1,4,5 and K351Nfs*21 is novel and reported as likely pathogenic.

Cascade screening of immediate family members was carried out (Figure 2 and Table 1) and identified that her brother, aged in his early teens, was also affected. On review he was asymptomatic but was found to have an albumin-corrected plasma calcium of 2.7 mmol/L (10.8 mg/dL) and hypercalciuria (1.23 mole ratio (RI 0.06-0.45)). Like his sibling, the ratio of plasma 25-OH-D3 to 24,25-(OH)2D3 was also markedly elevated. Renal tract ultrasound identified no calculi or nephrocalcinosis. He was made aware that he was at increased risk of stone disease and advised to avoid vitamin D supplementation.

The index case had a subsequent pregnancy three years later, during which serum calcium was monitored monthly and remained within the normal range (maximum corrected calcium 2.6mmol/l) in the absence of vitamin D supplementation. She developed recurrent ICP and delivered another healthy infant at term.
The final diagnosis for this family was of familial hypercalcaemia due to abnormal vitamin D metabolism as a result of heterozygous CYP24A1 loss-of-function mutations, often referred to as idiopathic infantile hypercalcaemia (IIH)/CYP24A1-hypercalcaemia. Symptomatic hypercalcaemia was unmasked in the index case by vitamin D supplementation. Physiological changes of pregnancy may also be relevant, however, given she remained normocalcaemic in a subsequent pregnancy (without vitamin D supplementation), these are not likely to be the dominant precipitant.

Discussion.

Disordered vitamin D metabolism and hypercalcaemia due to CYP24A1 mutations

Vitamin D is metabolised through a series of hydroxylation steps, first in the liver to 25-OH-D$_3$ and then in the kidney by 1α-hydroxylase to the active form 1,25-(OH)$_2$D$_3$ (calcitriol). Calcitriol is in turn catabolised to inactive 1,24,25-(OH)$_3$D$_3$ and calcitrioic acid, by cytochrome P450 enzyme CYP24A1, formerly known as 24-hydroxylase, which is also responsible for inactivation of 25-OH-D$_3$. The importance of inactivation of 1,25-(OH)$_2$D$_3$ in the regulation of vitamin D metabolism and therefore calcium balance has only recently been recognised. In 2011, hypercalcaemia following bolus vitamin D supplementation was described in a series of six children. The authors described this condition as ‘familial idiopathic infantile hypercalcaemia’.¹ Affected individuals were identified as harbouring bi-allelic loss of function mutations in CYP24A1, and thus demonstrated increased sensitivity to vitamin D loading. Since then, cases of inactivating CYP24A1 mutations have been reported across a wide spectrum of ages, including three cases first identified during pregnancy, all of which received prenatal supplements containing vitamin D.²,³,⁴
IIH/CYP24A1-hypercalcaemia classically presents as symptomatic hypercalcaemia in infancy, however a recent review found that more than a third of currently reported patients with bi-allelic CYP24A1 mutations presented later in life. Many affected individuals are asymptomatic but hypercalciuria and renal calculi are common, both of which were identified in our index patient. Chronic kidney disease, with a decline in glomerular filtration rate has also been reported although it is unclear if this is a primary complication of the disease or a result of calculi and/or associated intervention. The variable penetrance is thought to be due to a combination of genetic and environmental factors with the cumulative dose of exogenous vitamin D playing a critical role. The influence of sunlight exposure, thus cutaneous vitamin D may also be important with higher levels of serum and urinary calcium seen during summer months.

Quantification of vitamin D metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides a sensitive and specific method for identifying IIH/CYP24A1-hypercalcaemia and can be carried out by 150-200 specialist laboratories worldwide at a cost of around US$40 per sample. A chromatographic approach that resolves 24,25(OH)\textsubscript{2}D\textsubscript{3} from 25,26(OH)\textsubscript{2}D\textsubscript{3}, as used in this case, is recommended to avoid misleading results due to the contamination of the 24,25(OH)\textsubscript{2}D\textsubscript{3} peak by 25,26(OH)\textsubscript{2}D\textsubscript{3}. In affected individuals, levels of 25-OH-D\textsubscript{3} may be elevated and 1,24,25-(OH)\textsubscript{3}D\textsubscript{3} and 24,25-(OH)\textsubscript{2}D\textsubscript{3} are very low or undetectable. As measurement 1,24,25-(OH)\textsubscript{3}D\textsubscript{3} is technically difficult, measurement of the ratio of 25-OH-D\textsubscript{3} to 24,25-(OH)\textsubscript{2}D\textsubscript{3}: is recommended with the result being markedly elevated (>140 using the method described above). This ratio correctly predicted both affected cases in our family despite the post-partum return to normocalcemia in the index case.
Diagnosis is confirmed by genetic analysis. A spectrum of mutations along the entire CYP24A1 gene have been identified,\textsuperscript{10,11} however the K351Nfs*21 mutation identified in this case has not previously been reported. The prevalence of IIH/CYP24A1-hypercalcaemia is unknown, however, almost 0.7\% of the general European population have been found to be heterozygous carriers of one of 4 common CYP24A1 loss of function alleles.\textsuperscript{10} As there are now over 20 mutations reported the true carrier frequency is likely to be significantly higher.

Management of IIH/CYP24A1-hypercalcaemia includes avoidance of vitamin supplementation, a low calcium-diet (if appropriate) and advice regarding sun-protection and maintenance of hydration. For symptomatic hypercalcaemia usual treatments including hydration, glucocorticoids, calcitonin and bisphosphonates have been used successfully.\textsuperscript{10} If hypercalcemia is refractory, consideration can be given to medication that induces surrogate vitamin D catabolism.\textsuperscript{12} Treatment with rifampicin, a potent inducer of CYP3A4, successfully treated hypercalcaemia in 2 cases of IIH, the mechanism postulated to be increased degradation of 1,25-(OH)\textsubscript{2}D\textsubscript{3} or its precursor 25(OH)D\textsubscript{3} in the absence of CYP24A1.\textsuperscript{13} Inhibition of vitamin-D synthesising enzymes by low dose fluconazole has also been successfully used in a small number of reported cases.\textsuperscript{14}

Calcium physiology during pregnancy

Maternal calcium metabolism adapts to accommodate the demands of the placenta and growing fetal skeleton, which contains around 30g of calcium by full term.\textsuperscript{15} Although the
majority of the calcium is accumulated during the third trimester, changes to calcium homeostasis begin to occur early in pregnancy. Expansion of circulating plasma volume reduces serum albumin concentrations and thus total serum calcium; however, albumin-corrected and ionized free calcium concentrations remain within the normal non-pregnant reference range. Renal and placental upregulation of calcitriol production, which may lead to a several fold increase in serum concentrations by the third trimester, contribute to this effect. Consequently fractional absorption of calcium from the small intestine increases two fold during the first trimester, a change that is sustained throughout the remainder of pregnancy. This in turn leads to increased renal filtration and urinary calcium excretion which may reach the hypercalciuric range. A further consequence of the upregulation of calcitriol is that parathyroid hormone levels are suppressed during the first trimester to levels that may even fall below the lower limit of normal. PTHrP, produced by placental and lactating mammary tissue, rises gradually throughout pregnancy peaking in the post-partum period and being sustained by lactation. To ensure there is adequate vitamin D to meet this demand and to prevent fetal vitamin D deficiency, guidelines for vitamin D supplementation during pregnancy have recently been introduced in a number of countries. Guidance in Australia, New Zealand and United States suggests consideration of vitamin D measurement for women at high risk of deficiency (those with darker skin, who avoid sun exposure, take photosensitising medications, or have liver or kidney disease) and supplementation is advised for pregnant women with low levels. As the index patient wore a hijab she would be considered at high risk for deficiency. Australia and New Zealand guidelines also
suggest that supplementation should be considered for all pregnant women at higher risk, without testing vitamin D levels.\textsuperscript{18,19} In the UK it is recommended that all women be advised early in pregnancy to supplement vitamin D.\textsuperscript{22} These recommendations are based on evidence that, depending on geographical location and climate, a sizeable proportion of women of child bearing age (over one third in NZ\textsuperscript{23}) have vitamin D levels below the recommended range and there is correlation between maternal vitamin D levels and vitamin D deficiency in the newborn.\textsuperscript{21} Widespread blood testing for vitamin D deficiency is not encouraged because the cost of testing is far greater than the cost of treatment and the potential harms from treatment have traditionally been considered small. This case demonstrates that harms from treatment can be significant as, in the setting of disordered calcitriol metabolism, maternal vitamin D supplementation can unmask significant maternal hypercalcaemia. There is also evidence of harm with increased rates of infantile hypercalcaemia being reported in Australia since the introduction of guidelines in 2006. Of first measured serum calcium in infants under 6 months at a single laboratory hypercalcaemia was detected in 1.1\% in 2005-2007 and increased to 8.7\% in 2011-2013.\textsuperscript{24} During the latter period, 13 infants were diagnosed with IIH with raised 1,25-(OH)\textsubscript{2}D\textsubscript{3} in keeping with an abnormality of CYP24A1. Infants had associated significant morbidity including symptomatic hypercalcemia and nephrocalcinosis. Of these infants, twelve had mothers who had received prenatal vitamin D3 supplementation.

Overall, hypercalcaemia in pregnancy is rare. Primary hyperparathyroidism (PHPT) accounts for the majority of cases but still affects less than 0.1\% of reproductive age
women. In our patient PHPT was excluded based on suppressed PTH. There are a broad range of other causes of hypercalcaemia in pregnancy including malignancy, granulomatous disease and excessive calcium and alkali ingestion. In this case, as clinical assessment was not suggestive of malignancy and the response to steroids was not consistent with granulomatous disease, further investigation was carried out. The very high calcitriol concentration early in the pregnancy raised the possibility of a disorder of vitamin D metabolism. Hypercalcemia due to abnormalities of Vitamin D metabolism include vitamin D intoxication, IIH due to mutations of SLC34A1 (encoding renal proximal sodium-phosphate cotransporter Na-Pi-IIa) and, as identified in this case, IIH due to loss of function mutations of CYP24A1.

Conclusion
Hypercalcaemia due to disorders of vitamin D metabolism have previously been described but remain poorly recognized. IIH due to loss of function mutations in \textit{CYP24A1} should be considered in the differential diagnosis of hypercalcaemia or hypercalciuria in all age groups. Pregnancy (when there is an upregulation of calcitriol production) and, perhaps more importantly, a trend to supplement vitamin D, can precipitate symptomatic hypercalcaemia in affected patients and result in significant morbidity to both the mother and infant.

The ratio of 25-OH-D\textsubscript{3} to 24,25-(OH)\textsubscript{2}D\textsubscript{3} provides a sensitive and specific method for predicting the presence of \textit{CYP24A1} mutations, even during periods of normocalcaemia and diagnosis is confirmed through genetic analysis. Cascade screening of family members of individuals with \textit{CYP24A1} mutations is important and should be considered at adulthood, or earlier if symptomatic. Affected asymptomatic individuals benefit from diagnosis through prevention of unnecessary investigation of hypercalcaemia and awareness of the importance of avoiding vitamin D supplementation, particularly in pregnancy.
References


24. Amato LA et al. Increased rate of infantile hypercalcaemia following guidelines

<table>
<thead>
<tr>
<th></th>
<th>Calcium (mmol/L) (2.2-2.6)</th>
<th>PTH (pmol/L) (1.6-7)</th>
<th>Urine Ca:Cr ratio (mole ratio) (0.06-0.45)</th>
<th>25-OH-D$_3$ (nmol/L) (50-150)</th>
<th>1,25-(OH)$_2$D$_3$ (pmol/L) (65-175)</th>
<th>24,25-(OH)$_2$D$_3$ (nmol/L)</th>
<th>25-OH-D$_3$:24,25-(OH)$_2$D$_3$ Ratio (5-25)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Index (II-2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 weeks pregnant</td>
<td>2.9</td>
<td>0.7</td>
<td>2.09</td>
<td>116</td>
<td>380</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Index (II-2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-partum</td>
<td>2.6</td>
<td>1.8</td>
<td>0.76</td>
<td>57</td>
<td>210</td>
<td>0.10</td>
<td>594</td>
</tr>
<tr>
<td><strong>Index (II-2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second pregnancy 19 weeks</td>
<td>2.6</td>
<td>1.5</td>
<td>1.14</td>
<td>29</td>
<td>436</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>I-1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>3.0</td>
<td>0.37</td>
<td>78</td>
<td>98</td>
<td>6.9</td>
<td>11.3</td>
</tr>
<tr>
<td><strong>I-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>3.4</td>
<td>0.26</td>
<td>61</td>
<td>134</td>
<td>2.1</td>
<td>28.6</td>
</tr>
</tbody>
</table>
Table 1. Summary of biochemical investigations undertaken for each consenting family member.

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II-3</td>
<td>2.4</td>
<td>3.9</td>
<td>0.14</td>
<td>50</td>
<td>183</td>
<td>2.5</td>
</tr>
<tr>
<td>II-4</td>
<td>2.7</td>
<td>0.9</td>
<td>1.23</td>
<td>82</td>
<td>188</td>
<td>0.04</td>
</tr>
</tbody>
</table>
Figure 2. The index case (II-2) is indicated by the bold arrow. Affected family members are shown as solid black symbols. Family members carrying either mutation are indicated with a black dot. The patient's brother (II-1) refused consent for mutation testing.
Figure 1: LC-MS/MS analysis of 24,25-(OH)$_2$D$_3$ and 1,25-(OH)$_2$D$_3$. Quantitative assay of vitamin D metabolites including 24,25-(OH)$_2$D$_3$ and 1,25-(OH)$_2$D$_3$ involves dilution with specific deuterated internal standards, protein precipitation, extraction, and derivatization with DMEQ-TAD prior to LC-MS/MS analysis. A representative chromatogram of m/z 762→468+484 is shown, based on immunextraction with anti-1,25-(OH)$_2$D$_3$ antibody. Derivatization of vitamin D metabolites with DMEQ-TAD yields both 6S and 6R isomers, which are chromatographically resolved. As 24,25-(OH)$_2$D$_3$ and 1,25-(OH)$_2$D$_3$ share the same molecular mass and certain fragment ions, both metabolites can be observed on the m/z 762→468+484 trace.